Compare First Citizens BancShares Inc (FCNCA) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? First Citizens BancShares Inc trades at $2,052.8 (market cap $23.01B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: First Citizens BancShares Inc is far larger — about 2.7× Hinge Health Inc. Class A Common Stock's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 30 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FCNCA | HNGE | |
|---|---|---|
Market Cap | $23.01B | $8.48B |
Volume | 64,069 | 879,799 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $105.14 |
52-Week Low | $1.64K | $31.17 |
Typical Hold Time | 30 Days | 0 Days |
Dividend Yield | 0.4% | — |
Enterprise Value | — | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCNCA trades at $2,075.12, down 0.35% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $57.09 per share, beating estimates, and maintains a net income margin of 25.23%. Recent news includes a $157 million financing deal and branch expansion initiatives, signaling growth. Cash flow improved to a net positive $630 million in 2026 from a slight deficit in 2025.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but technical bearishness and high institutional hold ratings suggest near-term caution. Key risks include execution of expansion and interest rate sensitivity. The stock offers value with a P/E of 11.13, yet requires monitoring of technical levels for entry.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
